Cipla partners with Hetero to launch biosimilar anaemia drug

Pharma major Cipla on Thursday announced a collaboration with Hetero Drugs to launch a medication under the Actorise brand for treatment of anaemia caused due to chronic kidney disease.

Cipla makes user-friendly AIDS drug for African kids

Indian drug major Cipla is working with a global health NGO to manufacture the first user-friendly pediatric HIV/AIDS drug targeted at millions of African children who are currently being forced to take medicine that is unpalatable - to say the least.

Cipla launches biosimilar for rheumatic disorders in India

Drug major Cipla on Wednesday said it has launched biosimilar of Etanercept under the brand name `Etacept` used for treatment of rheumatic disorders in India.

India revokes patent on Merck & Co`s asthma drug

Indian Patents Office has revoked a patent for an asthma drug held by US-based Merck & Co following a challenge from domestic pharma firm Cipla.

HC order against marketing of Cipla`s anti-cancer drug stayed

The Supreme Court today stayed for a month a Delhi High Court order restraining pharma major Cipla from marketing its anti-cancer drug "Sunitinib."

Cipla slashes cancer drug prices by up to 64%

Giving some relief to cancer patients, pharma major Cipla today slashed prices of its three generic cancer drugs by up to 64 per cent.

Cipla`s anti-malaria drug receives WHO pre-qualification

Drug firm Cipla today said an anti-malarial drug developed by Drugs for Neglected Diseases initiative (DNDi) has received pre-qualification from the World Health Organisation (WHO).

Cipla launches HIV/AIDS treatment kit at Rs 158

Drug major Cipla today said it has launched `Qvir`, a four-drug kit priced at Rs 158 per kit to be used for treating HIV/AIDS.

Cipla launches HIV/AIDS treatment kit at Rs 158

Drug major Cipla today said it has launched `Qvir`, a four-drug kit priced at Rs 158 per kit to be used for treating HIV/AIDS.

Cipla slashes cancer drug prices by up to 76%

Drug major Cipla today slashed the prices by up to 76% of its generic drugs, used in treating cancers of brain, lung and kidney.

Cipla, DNDi to launch new malaria drug

Drug firm Cipla on Tuesday said it plans to launch fixed-dose combination anti-malarial drug in India in partnership with non-profit organisation, Drugs for Neglected Diseases Initiative (DNDi).

WHO adds Cipla`s two HIV drugs in prequalified list

The WHO said it will again add two HIV drugs from India`s Cipla in its prequalified list.

WHO adds Cipla`s two HIV drugs in prequalified list

The WHO said it will again add two HIV drugs from India`s Cipla in its prequalified list.

NPPA slaps Rs 20-cr fine on Cipla for overcharging

Pharma company Cipla Ltd on Monday
said it has received notices, demanding about Rs 20.15 crore,
from drug price regulator for allegedly over-pricing two
drugs.

Cipla to raise Rs 676 cr via QIP issue

Drug Firm Cipla on Friday said it will raise Rs 676 crore through the issue of equity shares on institutional placement basis.

Cipla’s kidney cancer drug given nod by Delhi HC

The Delhi HC directed
Drug Controller General of India to process the licence
application of Cipla for production and sale of generic
version of global pharma major Bayer Corporation`s liver and
kidney cancer drug `Nexavar`.

Cipla’s kidney cancer drug given nod by Delhi HC

The Delhi HC directed
Drug Controller General of India to process the licence
application of Cipla for production and sale of generic
version of global pharma major Bayer Corporation`s liver and
kidney cancer drug `Nexavar`.

SC refuses relief to Roche on patent plea against Cipla

The Supreme Court Friday refused to give any relief to Swiss pharma firm Hoffman La Roche Ltd that had challenged a Delhi High Court order allowing Cipla to manufacture and sell a generic version of lung cancer drug `Erlotinib`.

Cipla to raise Rs 1,500 cr by issue of shares

Drug maker Cipla on Friday said it will raise Rs 1,500 crore from international market by issue of securities.

Cipla plans capex of up to Rs 1,500 cr; to tap markets

Leading pharma company Cipla Ltd
on Wednesday said it envisages a capital expenditure of up to Rs
1,500 crore for which it will tap the markets.